Sustained drug delivery implant

摘要

Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.

主权项

1. A solid intraocular implant for the treatment of a posterior ocular condition in a human patient, the solid intraocular implant consisting of:
a brimonidine free base in an amount of about 40% by weight to about 60% by weight of the implant, based on the total weight of the implant; and a biodegradable polymer matrix comprising an acid end-capped poly (D, L-lactide) polymer and a 75:25 poly (D,L-lactide-co-glycolide) polymer; wherein the weight ratio of the acid end-capped poly (D, L-lactide) polymer to the 75:25 poly (D,L-lactide-co-glycolide) polymer is 1:1; and wherein the implant has a brimonidine free base delivery duration of two months to four months when placed in the eye of a human; and wherein the implant has a polymer matrix degradation time in the range of about three months to about six months when placed in the eye of a human.